News | Image Guided Radiation Therapy (IGRT) | April 30, 2018

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

New MR pulse sequences and imaging enhancements provide cutting-edge tumor and healthy tissue visualization for MR-guided radiotherapy

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

April 30, 2018 — ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac radiotherapy system. Designed to improve tumor and soft tissue visualization, these enhancements to MRIdian's SmartVision MR image guidance are expected to further improve the precision by which radiation is delivered to treat cancer.

MRIdian's SmartVision allows oncologists to visualize tumors and surrounding organs with diagnostic-quality MR imaging during treatment delivery. Building on the current technology are new T1w and T2w MR pulse sequences, both being developed to improve high-definition visualization and enhance the contrast between cancerous and healthy tissues. Also being developed for MRIdian's SmartVision, diffusion weighted imaging (DWI) may be used to distinguish between tumor and normal tissues and potentially assess and predict tumor response to radiation therapy.

Other enhancements to MRIdian's SmartVision include a 2-times increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second. The latest enhancements under development also include 2 times higher image resolution and a 2 times improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.

MRIdian continuously detects the shape and location of tumors and organs-at-risk (OAR) in real-time, and automatically turns radiation beams on and off when positional changes occur. Enabled by faster, higher-resolution imaging, the next-generation SmartVision will further support the clinician's ability to visualize healthy tissue and target the tumor.

ViewRay demonstrated the new MR pulse sequences, along with increased imaging speed and resolution, during the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), April 21-24 in Barcelona, Spain.

The new pulse sequences, increased image resolution and imaging frame rates are currently a technology under development and only available for sales in the European Economic Area. They are works in progress and are not available for commercial sales in the United States.

For more information: www.viewray.com

 

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
A cutting-edge magnet resonance imaging (MRI) technique to detect iron deposits in different brain regions can track declines in thinking, memory and movement in people with Parkinson's disease #Parkinsons #MRI

Summary steps of the processing pipeline for QSM reconstruction (phase pre-processing and map estimation) and whole brain/regional analysis. ANTs, advanced normalisation tools; MP-RAGE, magnetisation-prepared, 3D, rapid, gradient-echo; MSDI, multi-scale dipole inversion; QSM, quantitative susceptibility mapping; ROI, region of interest; SWI, susceptibility weighted imaging.

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — A cutting-edge...
Two magnetic resonance imaging (MRI) findings — joint capsule edema and thickness at the axillary recess, specifically — proved useful in predicting stiff shoulder in patients with rotator cuff tears, according to an ahead-of-print article in the May issue of the American Journal of Roentgenology (AJR)

A: Oblique coronal fat-suppressed T2-weighted MR image shows normal hypointense joint capsule at axillary recess (arrow). Note full-thickness tear of supraspinatus tendon (arrowheads) B: Oblique sagittal proton density MR image shows preserved subcoracoid fat triangle (asterisk). Image courtesy of the American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | February 20, 2020
February 20, 2020 — Two ma...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i